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ABSTRACT: Anti-PEG antibodies have been reported to mediate the
accelerated clearance of PEG-conjugated proteins and liposomes, all of
which contain methoxyPEG (mPEG). The goal of this research was to
assess the role of the methoxy group in the immune responses to mPEG
conjugates and the potential advantages of replacing mPEG with
hydroxyPEG (HO-PEG). Rabbits were immunized with mPEG, HO-PEG,
or t-butoxyPEG (t-BuO-PEG) conjugates of human serum albumin,
human interferon-α, or porcine uricase as adjuvant emulsions. Assay plates
for enzyme-linked immunosorbent assays (ELISAs) were coated with
mPEG, HO-PEG, or t-BuO-PEG conjugates of the non-cross-reacting
protein, porcine superoxide dismutase (SOD). In sera from rabbits
immunized with HO-PEG conjugates of interferon-α or uricase, the ratio
of titers of anti-PEG antibodies detected on mPEG-SOD over HO-PEG-
SOD (“relative titer”) had a median of 1.1 (range 0.9−1.5). In contrast, sera from rabbits immunized with mPEG conjugates of
three proteins had relative titers with a median of 3.0 (range 1.1−20). Analyses of sera from rabbits immunized with t-BuO-PEG-
albumin showed that t-butoxy groups are more immunogenic than methoxy groups. Adding Tween 20 or Tween 80 to buffers
used to wash the assay plates, as is often done in ELISAs, greatly reduced the sensitivity of detection of anti-PEG antibodies.
Competitive ELISAs revealed that the affinities of antibodies raised against mPEG-uricase were c. 70 times higher for 10 kDa
mPEG than for 10 kDa PEG diol and that anti-PEG antibodies raised against mPEG conjugates of three proteins had >1000
times higher affinities for albumin conjugates with c. 20 mPEGs than for analogous HO-PEG-albumin conjugates. Overall, these
results are consistent with the hypothesis that antibodies with high affinity for methoxy groups contribute to the loss of efficacy of
mPEG conjugates, especially if multiply-PEGylated. Using monofunctionally activated HO-PEG instead of mPEG in preparing
conjugates for clinical use might decrease this undesirable effect.
■ INTRODUCTION
Less than a decade after the first reports of the advantages of
coupling proteins to the “non-immunogenic” polymer, poly-
(ethylene glycol) (PEG),
1−3 Richter and Åkerblom provided
evidence for the induction of anti-PEG antibodies in rabbits
exposed to methoxyPEG (mPEG) conjugates of proteins
4 and
for the presence of anti-PEG antibodies in the sera of a small
percentage of healthy blood donors.
5 Nevertheless, during more
than three decades of research and the approval for clinical use
of numerous PEGylated proteins and other PEGylated thera-
peutic agents, relatively few research groups have focused on the
immunogenicity and antigenicity of the polymer component of
PEGylated drugs (reviewed by Armstrong
6 a n db yS ue ta l .
7).
Since all of the approved PEGylated drugs, including proteins,
8−10
an aptamer,
11 and “stealth” liposomes,
12 contain mPEG, the role
of the methoxy group of mPEG in the immune responses to
PEGylated drugs and the potential advantages of using
hydroxyPEG (HO-PEG), rather than mPEG, have been of
particular interest in our research
13,14 (see Figure 1).
In a series of research reports and patents that have been
published since 1999, Roffler, Cheng, and their colleagues
described the development of a series of mouse monoclonal
antibodies (mAbs) directed against the backbone of PEG.
7,15−21
They demonstrated the utility of such mAbs for the sensitive
detection and quantitation of PEGylated drugs
7,18 and for the
removal of potentially toxic PEGylated drugs from the circu-
lation.
7,18−21 Several of these mAbs are available commercially
from Abnova (Taipei City, Taiwan). Murine and rabbit anti-PEG
mAbs and assay kits incorporating anti-PEG mAbs are now
available from several other companies (e.g., ANP Technologies,
Newark, DE; Epitomics, Burlingame, CA; Life Diagnostics, Inc.,
West Chester, PA; Meridian Life Science, Inc., Saco, ME; Silver
L a k eR e s e a r c hC o r p . ,M o n r o v i a ,C A ) .T h em a j o r i t yo ft h e s e
mAbs are directed against the PEG backbone, but at least one of
them is directed against the methoxy group of mPEG (Epitomics,
Clone PEG-B-47).
Other research groups have investigated the roles of
polyclonal anti-PEG antibodies elicited in experimental animals
and patients in altering the pharmacokinetics and pharma-
codynamics of PEGylated agents that have been approved for
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red blood cells
22,23 and PEGylated liposomes,
24−29 as well as
PEGylated proteins (reviewed by Armstrong
6). Various tech-
niques have been used to detect and characterize such
antibodies, but the most widely used methods are enzyme-
linked immunosorbent assays (ELISAs). These are used in
various formats, including direct ELISAs and competitive
ELISAs (see Scheme 1). In direct ELISAs, the independent
variable is the dilution of immune serum. In competitive
ELISAs, a single dilution of serum is tested in the presence of
increasing concentrations of competitors, such as uncon-
jugated PEGs or PEG-protein conjugates. In many publi-
cations and patents in which anti-PEG antibodies are measured
by ELISAs, at least some of the washes of the assay plates
contain Tween 20 or Tween 80 (polyoxyethylene sorbitan
monolaurate or polyoxyethylene sorbitan monooleate, respec-
tively).
7,19−21,30−32 Therefore, we investigated the effects of
these PEG-containing detergents on the titers of anti-PEG
antibodies detected by direct ELISAs (see Figures 1 and 5).
Since the terms antigenicity and immunogenicity are some-
times used imprecisely, it seems useful to specify that, in this
report, immunogenicity refers to the ability of substances,
e.g., protein conjugates of mPEG, HO-PEG, or t-butoxyPEG
(t-BuO-PEG), to induce the production of antibodies in experi-
mental animals or in humans. In contrast, antigenicity refers to
the abilities of various substances, e.g., unconjugated PEGs or
PEG-protein conjugates, to bind to anti-PEG antibodies to which
they are exposed in vitro (see Scheme 1). In this research, the
immunogens were conjugates of recombinant human interferon-α
(IFN-α), porcine uricase, or human serum albumin (albumin),
which contained between 1 and 17 molecules of PEG per protein
molecule or subunit. The antigens used to coat the assay plates
were conjugates of an unrelated protein, porcine Cu−Zn
superoxide dismutase (SOD), to which the same small number
of molecules of mPEG, HO-PEG, or t-BuO-PEG of the same
size (10 kDa) were coupled using the same activation chemistry.
In competitive ELISAs, the competitors were free mPEG, HO-
PEG, or t-BuO-PEG or conjugates of albumin containing an
average of c. 20 molecules of mPEG or HO-PEG per molecule
of albumin.
Finally, since the results of the immunologic studies described
herein are consistent with the hypothesis that PEG-protein con-
jugates synthesized with monofunctionally activated HO-PEG
might be less antigenic and/or less immunogenic than the analo-
gous mPEG conjugates, we performed experiments to compare
the potencies in cell culture of analogous mPEG and HO-PEG
conjugates of two recombinant human cytokines.
■ EXPERIMENTAL PROCEDURES
Reagents and Supplies. Reagents were from Sigma-
Aldrich Chemical Co. (St. Louis, MO) unless otherwise noted.
PEG molecular weight standards and 10 kDa mono-t-butoxyPEG
were from Polymer Laboratories (Shropshire, UK, now part of
Agilent Technologies, Santa Clara, CA). Other PEGs were from
NOF Corporation (Tokyo, Japan), Shearwater Polymers
(Huntsville, AL, now part of Nektar Therapeutics, San
Francisco, CA) or SunBio (Anyang City, South Korea), as
indicated. Human interferon-α-2b (IFN-α) was from Tianjin
Hualida Bioengineering Co. (Tianjin, China). Erythropoietin
BRP European Pharmacopoeia Reference Standard (35280 IU/
0.25 mg) and Mircera (100 μg/0.3 mL, Roche) were obtained
from Bioassay GmbH (Heidelberg, Germany). Recombinant
human erythropoietin-α (EPO, CYT-201) that was used for the
synthesis of PEG conjugates was from ProSpec (Rehovot,
Israel). Recombinant porcine uricase was from Bio-Technology
G e n e r a lL t d .( R e h o v o t ,I s r a e l ,n o wp art of Ferring S.A., Saint-Prex,
Switzerland). Recombinant human granulocyte-macrophage
colony-stimulating factor (GM-CSF) was obtained from Berlex
Figure 1. Partial structures of methoxyPEG, hydroxyPEG, and
t-butoxyPEG and structures of Tween 20 and Tween 80. In the
structures of the PEGs, R designates the rest of the polymer, including
the proximal terminal group that reacts with the protein to form PEG
conjugates; the domains that may serve as epitopes for the formation
of anti-PEG antibodies, namely, the distal terminal groups (in shaded
ovals) and the PEG backbone, are indicated. In the structures of
Tween 20 and Tween 80, R designates the alkyl groups of the fatty
acids that distinguish these two detergents from each other (lauric and
oleic acids, respectively); 8Z designates the configuration around the
double bond in the heptadecenyl chain.
Scheme 1. Schematic of Enzyme-Linked Immunosorbent
Assays (ELISAs) for Determining the Titer of Anti-PEG
Antibodies by Direct ELISAs, Using Serial Dilutions of
Serum from Immunized Rabbits, or for Determining the
Relative Affinities of Binding to Various Competitors, Such
as Free PEGs or PEG-Protein Conjugates, Using a Constant
Dilution of Serum and Increasing Concentrations of the
Competitors
a
aLinkage of the secondary antibody (goat-anti-rabbit IgG) to
horseradish peroxidase (HRP) enables colorimetric quantitation of
the binding of the primary antibody to the assay plate.
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logical Products (Elkhart, IN) was used as human serum albumin.
Daudi cells and TF-1 cells were from ATCC (Manassas, VA).
Goat serum and most reagents used for cell culture were from
GIBCO (now part of Invitrogen/Life Technologies, Carlsbad,
CA). Alamar Blue, used for cell culture assays, Novex NuPAGE
gels and Sypro Ruby were also from Invitrogen. Microplates used
for fluorometric assays of cell growth were from Greiner Bio-One
North America, Inc. (Monroe, NC). Immulon 2 HB microplates
used for ELISAs were from Thermo Scientific (Rochester, NY).
Trifluoroacetic acid (TFA) was from Supelco (Bellefonte, PA).
Nonfat dry milk solids were from Western Family (Portland, OR).
Spectra/Por 1 dialysis tubing was from Spectrum Laboratories
(Rancho Dominguez, CA).
PEGylation Reagents and PEG-Protein Conjugates Used
as Immunogens, Antigens, and Competitors in Immuno-
logic Assays and in Cell Culture Assays. Table 1 summarizes
the reagents used to immunize the rabbits and as antigens or
competitors in the ELISAs. Details about the synthesis, puri-
fication, and physicochemical analyses of (1) the activated
HO-PEGs and t-BuO-PEG; (2) the PEG-protein conjugates
listed in Table 1, and (3) the HO-PEG conjugate of erythro-
poietin used in the cell culture assays are provided in the Supporting
Information, which includes seven figures, numbered S1 through S7.
Determination of the Number of PEG Molecules Coupled
per Protein Molecule. Size-exclusion chromatography (SEC)
was performed on Superdex 200 or TSK G-5000PWXL columns
from which the eluates were monitored by both UV absorbance
and refractive index (RI). Peaks containing PEG-protein
conjugates were analyzed by the method of Kunitani et al.
33
This method was used to characterize PEG conjugates of SOD,
IFN-α, EPO, recombinant porcine uricase, and human serum
albumin (albumin). These conjugates contained between 1 and
22 molecules of PEG per protein molecule or subunit. For
conjugates of SOD, IFN-α, EPO, and uricase coupled to fewer
than c. 5 molecules of PEG per protein subunit, the results for
the PEG-to-protein ratio calculated from the SEC elution pro-
files were confirmed by polyacrylamide gel electrophoresis in
the presence of sodium dodecyl sulfate (SDS-PAGE) on Novex
NuPAGE gels. Replicate gels were stained for protein with
Coomassie blue R-250 or Sypro Ruby and for PEG with a solution
of KI and I2 mixed with BaCl2, by an adaptation of the method of
Skoog.
34
Animals and Immunizations. Eight groups of three rabbits
were immunized with a PEG conjugate of one of the following
proteins: IFN-α, porcine uricase, or human serum albumin.
Specific pathogen-free New Zealand white rabbits were injected
with PEGylated immunogens on days 0, 7, 14, 28, 56, and 84.
The first immunization was in complete Freund’s adjuvant. Sub-
sequent immunizations were in incomplete Freund’sa d j u v a n t .
Blood was collected prior to immunization (prebleed) and 6, 10,
and 14 weeks after the first immunization (Bleeds 1, 2, and 3).
Serum was prepared from each bleed by centrifugation and was
kept frozen at −40 °C until use. All rabbit procedures were
performed at Lampire Biological Laboratories (Pipersville, PA)
by AAALAC-certified technicians in accordance with IACUC-
approved protocols.
Direct Enzyme-Linked Immunosorbent Assays (Direct
ELISAs). The PEGylated antigens used in direct ELISAs
consisted of conjugates of SOD with 10 kDa mPEG, 10 kDa
HO-PEG, or 10 kDa t-BuO-PEG that were synthesized, purified,
and analyzed as described in the Supporting Information. The
conjugates contained an average of c. 2−3 molecules of PEG per
16 kDa subunit of SOD. Concentrations of PEGylated antigens
are expressed as protein concentrations (μg/mL). For most ex-
periments, 100 μL of a solution of PEGylated SOD (10 μg/mL)
prepared in 0.1 M sodium carbonate buffer, pH 10.3, was used
to coat each well of the 96-well plates. When IFN-α was used as
the antigen, 100 μL of a solution of 10 μg/mL of IFN-α in
sodium carbonate buffer was placed in the wells, corresponding
to 1 μg/well.
Immulon 2 HB 96-well microplates were coated with IFN-α
or PEG-SOD by incubation overnight at 4 °C. Removal of
unbound antigen and all washes of the plates were performed
with a Denley Wellwash 4 plate washer (Needham Heights,
MA). After removal of unbound antigen, the wells were washed
three times with phosphate-buffered saline (PBS) and then
incubated for 1 h at room temperature with 300 μL/well of
Blocking Buffer (5% (w/v) nonfat dry milk solids in PBS).
After removal of the Blocking Buffer, the plates were washed
three times with PBS. Serial dilutions of rabbit sera in PBS
containing 2% (v/v) goat serum (PBS-G) were added to the
plates (100 μL/well), which were incubated for 1 h at 37 °C.
The plates were then washed three times with PBS. No
detergents such as Tween 20 or Tween 80 were included in the
wash buffers except as indicated in Figure 5.
Goat anti-rabbit IgG (H & L chain specific) (1 mg/mL)
conjugated to horseradish peroxidase (HRP) was used as the
secondary antibody (Sigma) (see Scheme 1). For most assays,
Table 1. Reagents Used as Immunogens and as Antigens and
Competitors in ELISAs
Immunogens
polymer component
protein component end group PEG M.W. # of PEGs
human interferon-α methoxy 20 kDa 1
20 kDa 2
hydroxy 20 kDa 1
20 kDa 2
porcine uricase methoxy 10 kDa 2.3
a
hydroxy 10 kDa 2.3
a
human serum albumin methoxy 10 kDa 17
t-butoxy 10 kDa 17
Antigens
polymer component
protein component end group
PEG
M.W.
# of
PEGs
porcine superoxide dismutase (SOD) methoxy 10 kDa 2.5
b
hydroxy 10 kDa 2.5
b
t-butoxy 10 kDa 2.5
b
human interferon-α (No PEG)
Competitors
free polymers mPEG 10 kDa
20 kDa
PEG Diol 10 kDa
20 kDa
polymer component
PEG-albumin conjugates end group PEG M.W. # of PEGs
methoxy 10 kDa 17−19
hydroxy 10 kDa 17−22
aNumber of PEGs per uricase subunit.
bNumber of PEGs per SOD
subunit.
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100 μL/well contained 0.01 μg of antibody protein. If the
peroxidase activity detected under the conditions described
below was too high to obtain a linear increase in absorbance for
at least 4 min, the secondary antibody was diluted 1/15 000 or
1/20 000 in PBS-G in subsequent experiments. After addition
of the secondary antibody, the plates were incubated for 45 min
at 37 °C. The plates were washed three times with PBS before
the addition of 200 μL/well of peroxidase substrate, which was
o-phenylenediamine dihydrochloride
35 (OPD), purchased as
SIGMAFAST OPD. The substrate solution was prepared as
close as possible to the time of use and stored briefly at room
temperature, shielded from light. The substrate consists of two
tablets (one OPD tablet and one urea hydrogen peroxide/
buffer tablet), which were dissolved in 21 mL of water. This
solution was filtered through a 0.2 μm syringe filter (Acrodisc
25 mm Syringe Filter, Pall Corporation, Ann Arbor, MI). The
absorbance at 440 nm of the colored conjugate formed with
peroxide was measured in a SpectraMax 250 microplate reader
(Molecular Devices, Sunnyvale, CA) in kinetic mode for 6 min
at 12 s intervals. The assay plate was shaken in the plate reader
for 15 s before the first reading and for 3 s before each
subsequent reading of the plate (see Scheme 1).
Competitive ELISAs. As in the direct ELISAs, Immulon 2
HB 96-well microplates were coated with mPEG-SOD, HO-
PEG-SOD, or t-BuO-PEG-SOD by incubation overnight at
4 °Cw i t h1 0 0μL/well of antigens at 10 μg/mL in 0.1 M sodium
carbonate buffer, pH 10.3. After removal of unbound antigen
and three washes with PBS, the plates were blocked for 1 h at
room temperature with 300 μL/well of Blocking Buffer. The
plates were washed three times with PBS. Serial dilutions of the
competitors in PBS-G (50 μL/well) were added to the wells,
followed by 50 μL/well of diluted rabbit serum in PBS-G.
Dilutions of sera used for competitive ELISAs were calculated
to correspond to the highest dilution factor that provided
maximal binding in direct ELISAs. Therefore, for competitive
ELISAs, sera with higher titers were diluted more extensively
than sera with lower titers. The dilution factors, which are
indicated in the legends of Figures 6−8 and Figure 9B, ranged
from 1/320 to 1/10 000. Samples were mixed by shaking the
plate in the plate reader for 10 s before it was incubated for 1 h
at 37 °C. After removal of unbound reactants, the plates were
washed three times with PBS. The addition of secondary
antibody, washing of plates, addition of HRP substrate, and
monitoring of absorbance of the colored product were
performed as described above for direct ELISAs.
Analysis of Data from ELISAs. The rates of increase in
absorbance at 440 nm during the period of measurement were
exported from the SpectraMax plate reader into Microsoft
Excel. Usually, the increase in absorbance was linear during the
first 4 min of measurements, with a correlation coefficient (R2)
greater than 0.98. For direct ELISAs, the rates (in milli-absorbance
units/min) were graphed against the log10 of the serum dilution.
For competitive ELISAs, the rates were graphed against the
log10 of the final concentration of each competitor, in units of
micromolar PEG.
Data in colorimetric assay units (mAU/min) were first
analyzed as a function of the log10 of the serum dilution (direct
ELISAs) or the log10 of the competitor concentration (competi-
tive ELISAs) using DPlot software (HydeSoft Computing, LLC,
Vicksburg, MS) to obtain the best fit to a sigmoid curve, using
the equation
=+ + + ⎡
⎣
⎤
⎦ y AB /1 1 0CD x ()
The results in colorimetric assay units were converted to per-
cent of the maximal binding by subtracting A (the minimal
value), dividing by B (the range of values), and multiplying by
100. The resultant values of the percent of the maximal binding
in direct and competitive ELISAs were plotted against the log10
of serum dilution or the log10 of competitor concentration,
respectively.
For direct ELISAs, the values of the parameters C and D
from DPlot were used to calculate the dilution of serum corre-
sponding to half-maximal binding of the antibodies to the assay
plate (D50), using the equation
= − D 10 CD
50
(/ )
The ratio of the values of D50 obtained when the same antiserum
was tested against mPEG-SOD and against HO-PEG-SOD (at the
same antigen concentration) was used as a measure of the relative
titer against the two types of PEG (see Figures 2−4a n dT a b l e2 ) .
Figure 2. Titers of antibodies to HO-PEG, mPEG, and interferon-α
were determined by direct ELISAs of sera prepared from each of three
monthly bleeds of rabbits immunized with either mPEG1-IFN-α (A)
or HO-PEG1-IFN-α (B). (A) Anti-PEG antibodies were measured on
assay plates coated with 2 μg/well of superoxide dismutase (SOD)
coupled to either 10 kDa HO-PEG (red symbols) or 10 kDa mPEG
(black symbols). Anti-IFN-α antibodies were measured on assay plates
coated with 1 μg/well of recombinant human IFN-α (blue symbols).
Mean values in sera from Bleeds 1, 2, and 3 were calculated from
results obtained with HO-PEG-SOD (red dashed line), mPEG-SOD
(black solid line), or IFN-α (blue solid line) as the antigen. Black
arrows indicate the ratios of titers detected against the various
antigens. (B) Sera from Bleeds 1, 2, and 3 of a rabbit immunized with
HO-PEG1-IFN-α were analyzed in the same way as described for (A).
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D from DPlot were used to calculate the competitor concen-
tration that inhibited 50% of the binding of the antibodies to the
antigen on the plate (IC50), using the equation
= − IC 10 CD
50
(/ )
The ratio of the values of IC50 for two competitors assayed at
the same dilution of a particular serum provides a measure of
the relative affinities of the antibodies being tested for those
competitors (see Figures 6−8 and 9B).
Cell Culture Assay of the Potencies of Interferon-α
and PEG Conjugates. Interferon-α and four PEG-IFN-α con-
jugates were assayed for their abilities to inhibit the proliferation
of Daudi cells, measured by a fluorometric assay with Alamar
Blue as the indicator.
36,37 Daudi cells are human lymphoblastic B
cells derived from a male patient with Burkitt’s lymphoma.
38
The growth medium was RPMI 1640 with 2 mM L-glutamine
containing 10% fetal bovine serum, 10 mM HEPES buffer,
1.5 g/L sodium bicarbonate, 1 mM sodium pyruvate, 1% (v/v)
Pen/Strep. and 5.4 g/L D-(+)-glucose. All components of the
medium were from GIBCO except for glucose, which was from
Sigma-Aldrich. The cells were grown at 37 °C in humidified air
containing 5% CO2, with twice-weekly passages.
Cells in the log-phase of growth (150 μL of a suspension in
growth medium of 250 000 cells/mL) were incubated for 4 h at
37 °C in humidified air containing 5% CO2 in 96-well, flat,
clear-bottom, black microplates. Serial dilutions in growth
medium (50 μL) of IFN-α or mPEG-IFN-α or HO-PEG-IFN-α
were added to the cells in the assay plates, which were incu-
bated for 72 h under the same conditions as for growth. Alamar
Blue (20 μL) was then added, and the incubation was con-
tinued for 4 h. The assay plates were shaken for 30 s on a
JitterBug orbital shaker (Boekel Scientific, Feasterville, PA)
both after the addition of the serial dilutions of IFN-α or the
PEG conjugates and after the addition of Alamar Blue. The
fluorescent signal was measured at excitation and emission
wavelengths of 544 and 589 nm, respectively, in a fluorescence
plate reader (Fluoroskan Ascent Model with Ascent software,
Thermo Labsystems, Waltham, MA).
As in the analysis of data from ELISAs, data for cell growth in
relative fluorescence units as a function of the concentration of
IFN-α or PEG-IFN-α were analyzed using DPlot software to fit
the equation
=+ + + ⎡
⎣
⎤
⎦ y AB /1 1 0CD x ()
Using the minimal value (A) and the range of values (B) from
the initial DPlot, the data were converted to Percent of Inhib-
itable Cell Growth, as shown in Figure 10A.
Figure 3. Titers of antibodies against mPEG and against HO-PEG
were determined by direct ELISAs of sera from groups of three rabbits
immunized with either mPEG1-IFN-α (A) or HO-PEG1-IFN-α (B).
(A) Percentages of maximal binding to mPEG-SOD (filled symbols,
solid curves) and to HO-PEG-SOD (open symbols, dashed curves)
and the ratio of titers on mPEG/HO-PEG (“relative titers”) are
indicated for three rabbits immunized with mPEG1-IFN-α. Data for
each of rabbits R8990, R9002, and R9003 are shown in green, black,
and orange, respectively. (B) Percentages of maximal binding to
mPEG-SOD (filled symbols, solid curves) and to HO-PEG-SOD
(open symbols, dashed curves) and the ratio of titers on mPEG/
HO-PEG are indicated for three rabbits immunized with HO-PEG1-IFN-α.
Data for each of rabbits R8991, R8995, and R8997 are shown in blue,
red, and gray, respectively.
Figure 4. Titers of antibodies against mPEG and HO-PEG in sera
from groups of three rabbits immunized with mPEG-uricase (A) or
HO-PEG-uricase (B) were determined by direct ELISAs. PEG-uricase
conjugates used as immunogens contained an average of 2.3 molecules
of 10 kDa mPEG or HO-PEG per uricase subunit. (A) Percentages of
maximal binding to mPEG-SOD (filled symbols, solid curves) and to
HO-PEG-SOD (open symbols, dashed curves) and the relative titers
on mPEG/HO-PEG are indicated for three rabbits immunized with
mPEG-uricase. Data for each of rabbits R579, R580, and R581 are
shown in orange, black, and green, respectively. (B) Percentages of
maximal binding to mPEG-SOD (filled symbols, solid curves) and to
HO-PEG-SOD (open symbols, dashed curves) and the relative titers
on mPEG/HO-PEG are indicated for three rabbits immunized with
HO-PEG-uricase. Data for each of rabbits R582, R583, and R584 are
shown in red, blue, and gray, respectively.
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and PEG Conjugates. The effects of EPO and of mPEG and
HO-PEG conjugates of EPO on the proliferation of TF-1 cells
were assessed using a fluorometric assay with Alamar Blue, as
described above for the assay of IFN-α and its PEG conjugates
using Daudi cells. TF-1 cells are factor-dependent erythroblastic
cells derived from the bone marrow of a male patient with
erythroleukemia.
39,40 Cells were cultured at 37 °Ci n
humidified air containing 5% CO2 in the same growth medium
as used for Daudi cells, except that the growth medium for TF-1
cells was supplemented with 2.4 ng/mL GM-CSF.
TF-1 cells were collected in the log phase of growth and were
centrifuged for 10 min at 1000 rpm at 4 °C. The supernatant
was removed and the pellet was resuspended twice in 10 mL of
assay medium, which is growth medium without added GM-
CSF, to minimize the residual concentration of GM-CSF. Cells
(100 μL of a suspension in assay medium of 100 000 cells/mL)
were mixed with 100 μL of serial dilutions of growth factors
(EPO or PEG-EPO conjugates) in assay medium in the wells of
a 96-well, flat, clear-bottomed, black microplate. The cells were
cultured for 72 h at 37 °C in humidified air containing 5% CO2.
Alamar Blue (25 μL) was then added and the incubation was
continued for 6 h. The plates were shaken for 30 s on a
JitterBug orbital shaker after the addition of the cell suspension
to the growth factor dilutions and after the addition of Alamar
Blue. The fluorescent signal was measured in a fluorescence
plate reader, as described above for the Daudi cell assay. Data in
relative fluorescence units were analyzed using DPlot software
and the same equation shown above for the analysis of data from
the Daudi cell assay. Using the minimal value (A)a n dr a n g eo f
values (B) from the initial DPlot, the data were converted to
Percent of Maximal Cell Growth, as shown in Figure 10B.
■ RESULTS
Immune Responses to MonoPEG Conjugates of
mPEG-Interferon-α and HO-PEG-Interferon-α Differ
throughout Immunization. Direct ELISAs were performed
on sera from three successive monthly bleeds of two rabbits
immunized with either mPEG1-IFN-α (Figure 2A) or HO-PEG1-
IFN-α (Figure 2B), using assay plates coated with mPEG-SOD,
HO-PEG-SOD, or IFN-α (see Scheme 1). Chromatographic
analyses of the PEG conjugates of SOD and IFN-α are provided
in Figures S3 and S4 of the Supporting Information, respectively.
The titers of antibodies detected after immunization with IFN-α
coupled to one molecule of 20 kDa mPEG (mPEG1-IFN-α)w e r e
highest with IFN-α as the antigen, somewhat lower with mPEG-
SOD, and lowest for HO-PEG-SOD as the antigen (Figure 2A).
There were no significant differences among the results obtained
with sera from Bleeds 1, 2, and 3 of this rabbit (represented by
triangles, circles, and squares, respectively). Analogous data for sera
from three bleeds of a rabbit immunized with IFN-α coupled to
one molecule of 20 kDa HO-PEG (HO-PEG1-IFN-α) are shown
in Figure 2B. In this case, the titers of anti-PEG antibodies
detected with mPEG-SOD and HO-PEG-SOD as the antigens
were indistinguishable from each other and were about 20 times
lower than the titer of antibodies detected against IFN-α.A si n
Figure 2A, there were no significant differences among the
results obtained with sera prepared from Bleeds 1, 2, or 3 of this
rabbit, which was immunized with HO-PEG1-IFN-α.
In contrast with the results in Figure 2, for 1 of the 23 rabbits
used in this research (R9003, which was immunized with
mPEG1-IFN-α), the titers of anti-PEG antibodies detected in
serum from Bleed 1 were lower than those detected in sera
from subsequent bleeds (data not shown). Therefore, all sub-
sequent experiments were performed on sera from Bleed 2
and/or Bleed 3 of each rabbit, which gave similar results for all
tested parameters.
Rabbits Immunized with mPEG1-Interferon-α, but not
with HO-PEG1-Interferon-α, Have Higher Titers of Anti-
PEG Antibodies Detected with mPEG-SOD than with
HO-PEG-SOD. In the sera of three rabbits immunized with
mPEG1-IFN-α, a relatively narrow range of titers of antibodies
was detected with mPEG-SOD as the antigen (solid curves
in Figure 3A) and a slightly wider range of lower titers of
Table 2. Relative Titers of Antibodies Detected with mPEG-SOD/HO-PEG-SOD as the Antigen in Sera from Bleeds 2 and/or 3
of 23 Rabbits Immunized with Eight PEGylated Protein Immunogens
relative titer relative titer
protein of immunogen
mPEG/protein
(PEG M.W.) rabbit # mean s.d. n
HO-PEG/protein
(PEG M.W.) rabbit # mean s.d. n
Human Interferon-α 1 (20 kDa) R8990 3.0 0.8 4 1 (20 kDa) R8991 1.1 0.1 2
R9002 3.0 0.3 4 R8995 1.0 0.03 2
R9003 4.8 0.9 5 R8997 0.9 0.2 4
Human Interferon-α 2 (20 kDa) R8993 2.7 0.5 4 2 (20 kDa) R8992 0.9 0.2 2
R9001 5.5 1.0 4 R8994 1.1 0.2 2
R9004
a R9000 0.9 0.1 2
Porcine Uricase 2.3/subunit (10 kDa) R579 20 4.8 4 2.3/subunit (10 kDa) R582 1.3 0.2 3
R580 3.1 0.6 3 R583 1.1 0.2 3
R581 18 4.8 5 R584 1.5 0.1 3
Human Serum Albumin 17 (10 kDa) R12056 3.0 0.5 4
R12057 1.1 0.1 3
R12058 2.6 0.6 3
Median 3.0 Median 1.1
Range 1.1−20 Range 0.9−1.5
t-BuO-PEG/protein (PEG M.W.)
Human Serum Albumin 17 (10 kDa) R12059 1.8 0.5 2
R12060 1.2 0.2 2
R12061 1.7 0.3 2
aRabbit R9004 died before Bleed 2.
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Figure 3A). The highest titer of anti-PEG antibodies detected
with mPEG-SOD (in serum from rabbit R9002) was c. 7 times
higher than the lowest titer (in serum from rabbit R8990). For
each serum sample, the ratio of the titers detected with mPEG-
SOD to those detected with HO-PEG-SOD is referred to in
this report as the “relative titer”. Among the three rabbits in this
experiment, the relative titers varied from 3 to 6 (indicated as
3× and 6×, respectively, in Figure 3A).
In sera from each of three rabbits immunized with HO-
PEG1-IFN-α, the titers of anti-PEG antibodies detected with
mPEG-SOD as the antigen (solid curves in Figure 3B) and with
HO-PEG-SOD as the antigen (dashed curves in Figure 3B)
were indistinguishable from each other. This was true although
the absolute titers of anti-PEG antibodies in the serum with the
highest titer (from rabbit R8995) were c. 20 times those in the
serum with the lowest titer (from rabbit R8997).
Rabbits Immunized with Multiply-PEGylated mPEG-
Uricase, but not HO-PEG-Uricase, Have Higher Titers of
Anti-PEG Antibodies Detected with mPEG-SOD than
with HO-PEG-SOD. Direct ELISAs similar to those shown in
Figure 3 were performed on sera from groups of three rabbits
immunized with mPEG or HO-PEG conjugates of porcine
uricase in which an average of 2.3 molecules of 10 kDa PEG
were coupled per uricase subunit (see Figure S6). This extent
of PEGylation corresponds to an average of about nine mole-
cules of PEG per uricase tetramer, which is the active form of the
enzyme.
14 The titers of anti-PEG antibodies for all three rabbits
immunized with this mPEG-uricase conjugate were indistin-
guishable when tested on assay plates coated with mPEG-SOD
(note the superposition of the three solid curves in Figure 4A).
However, there were differences among the titers of antibodies
detected in the same sera with HO-PEG-SOD as the antigen
(dashed curves). The relative titers of antibodies against mPEG/
HO-PEG varied from c. 4-fold for rabbit R580 to >20-fold for
rabbits R579 and R581.
In sera from three rabbits immunized with HO-PEG-uricase,
the titers of antibodies detected against either mPEG or HO-
PEG were nearly indistinguishable (Figure 4B). The relative
titers of antibodies against mPEG/HO-PEG varied only from
about 1.3 to 1.5 in this experiment, in contrast with the much
higher relative titers shown in Figure 4A.
Most Rabbits Immunized with mPEG Conjugates of
Three Proteins Have Higher Titers of Anti-PEG Anti-
bodies Detected with mPEG-SOD than with HO-PEG-
SOD, Unlike Those Immunized with HO-PEG-Proteins.
The results obtained in replicate analyses (between 2 and 5),
similar to those shown in Figures 2−4, of sera from 23 of the 24
rabbits immunized for this study are summarized in Table 2.
Since rabbit R9004 died before Bleed 2, no data for that rabbit
are included in the table.
On the basis of the mean values of the relative titers for all 11
rabbits immunized with mPEG conjugates of three proteins, the
median value of the relative titer was 3.0, with a range of 1.1−20.
In contrast, each of nine rabbits immunized with HO-PEG con-
jugates of IFN-α or uricase had similar titers of anti-PEG anti-
bodies detected on mPEG and HO-PEG antigens.
Sensitivity of Detection of Anti-PEG Antibodies Is
Decreased by Tween 20 or Tween 80. Many procedures
commonly used for the performance of direct or competitive
ELISAs include the use of the detergents Tween 20
7,19−21,30,31
or Tween 80
32 in the solutions with which the assay plates are
washed one or more times. The structures of these detergents
are shown in Figure 1. Two of the experiments performed to
assess the effects of Tween 20 or Tween 80 on the titers of anti-
PEG antibodies detected by direct ELISAs are shown in Figure 5.
Sera from two rabbits immunized with either mPEG-uricase or
HO-PEG-uricase were tested in direct ELISAs on replicate assay
plates coated with mPEG-SOD. In each experiment, one of the
assay plates was washed without any detergent, as was done in all
of the other ELISAs described in this report. The other assay
plate was washed before and after the addition of the secondary
antibody with PBS containing either 0.05% (v/v) Tween 20
(Figure 5A) or 0.1% (v/v) Tween 80 (Figure 5B).
When the assays were performed without the use of Tween
in the washes (solid curves), the titer of anti-PEG antibodies
detected in the serum of the rabbit immunized with mPEG-
uricase was only 2−2.5 higher than that of the rabbit immunized
with HO-PEG-uricase. In contrast, the titer of anti-PEG
antibodies in serum from the same rabbit that was immunized
with mPEG-uricase appeared to be higher by a factor of c. 70 or
c. 80 when Tween 20 or Tween 80, respectively, was used in the
washes before and after the addition of the secondary antibody
(dashed curves). Figure 5 also shows that the apparent titers of
Figure 5. Washing the assay plate with Tween 20 or Tween 80,
detergents that contain HO-PEG, decreased the titers detected by
direct ELISAs of sera from rabbits immunized with HO-PEG-uricase
(○, ●) or mPEG-uricase (Δ, ▲) and amplified the differences
between the titers of anti-PEG antibodies detected in sera from these
two rabbits. Direct ELISAs with mPEG-SOD as the antigen were
performed as described in Experimental Procedures, except that the
PBS used to wash one of the replicate assay plates before and after the
addition of the enzyme-linked secondary antibody contained either
0.05% (v/v) Tween 20 (A) or 0.1% (v/v) Tween 80 (B). Higher titers
were detected in the absence of detergent (filled symbols, solid curves)
than in the presence of Tween (open symbols, dashed curves). The
effects of each type of Tween on the results for the individual rabbits
immunized with either HO-PEG-uricase or mPEG-uricase are shown
by red arrows and black arrows, respectively. The ratios of titers
detected in sera from these two rabbits in the presence or absence of
Tween are shown by blue arrows.
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SOD, in the serum of a rabbit immunized with HO-PEG-uricase
were decreased c. 300-fold or c. 100-fold (red arrows) when
the plates were washed with buffers containing Tween 20 or
Tween 80, respectively. In contrast, washing the assay plates
with Tween 20 or Tween 80 decreased the apparent titers in
serum from the rabbit immunized with mPEG-uricase only
c. 8-fold or c. 5-fold, respectively (black arrows).
MethoxyPEG Binds More Tightly than PEG Diol to
Antibodies Raised against mPEG-Interferon-α and
mPEG-Uricase, but not to Antibodies Raised against
HO-PEG-Uricase. The results of competitive ELISAs with
10 kDa mPEG (filled circles) and 10 kDa PEG diol (open circles)
of three dilutions of serum from a rabbit immunized with
mPEG2-IFN-α are compared in Figure 6A. For all of the
tested dilutions of serum (1/500, 1/1000, and 1/2000), the
ratios of affinities for mPEG/PEG diol were between 30 and
40. On the other hand, the values of IC50 for each of the
competitors varied in a nonlinear fashion with the dilution
of the serum. Thus, a 4-fold decrease in the antibody
concentration (from 1/500 to 1/2000) resulted in a 2-fold
decrease in the values of IC50.
In Figure 6B, the potency of 10 kDa mPEG (black symbols)
is compared to that of 10 kDa PEG diol (red symbols) as com-
petitors for the binding to mPEG-SOD of antibodies elicited by
mPEG-uricase. The anti-PEG antibodies in the serum tested in
Figure 6B exhibited c. 70-fold higher affinity for mPEG than for
PEG diol of the same molecular weight. Similar results were ob-
tained with sera from the other two rabbits immunized with
mPEG-uricase (data not shown). In contrast, no significant dif-
ference was detected between the affinities of antibodies raised
against HO-PEG-uricase for 10 kDa mPEG vs 10 kDa PEG
diol, when tested on the same antigen (Figure 6C) or on HO-
PEG-SOD as the antigen (data not shown). These results indi-
cate that anti-PEG antibodies raised against mPEG conjugates
have much higher affinities for mPEG than for PEG diol, while
anti-PEG antibodies elicited by HO-PEG conjugates show no
selectivity for the end-group of the polymer.
Although competitive ELISAs on a single dilution of a single
serum sample provide information about the relative affinities
of those antibodies for various competitors (e.g., 10 kDa mPEG
vs 10 kDa PEG diol, as shown in Figure 6B), comparisons of
the values of IC50 for different serum samples do not provide a
valid comparison of affinities, because the values of IC50 do not
vary linearly with the concentration of antibodies in each
sample, as shown in Figure 6A.
Anti-PEG Antibodies against mPEG-Interferon-α or
mPEG-Uricase Bind Cooperatively to Multiply-
PEGylated mPEG-Albumin; Antibodies against HO-
PEG-Uricase Bind Similarly to PEG Diol and to HO-
PEG-Albumin. An albumin conjugate containing an average of
19 molecules of 10 kDa mPEG (mPEG19-albumin) and free
10 kDa mPEG were tested as competitors for the binding to
mPEG-SOD of antibodies raised against mPEG2-IFN-α (Figure 7A).
At the highest tested concentrations (c. 0.1−1 mM PEG), both
competitors blocked the binding to the assay plate completely.
In a range of lower concentrations, however, the multiply-
PEGylated albumin conjugate was much more potent as a
competitor than free mPEG. The molar concentration of free
mPEG that inhibited 50% of the binding (IC50) was c. 12 times
higher than the concentration of mPEG in the albumin con-
jugate that was similarly inhibitory.
Experiments analogous to those in Figure 7A were per-
formed on antiserum raised against mPEG-uricase containing
an average of nine molecules of mPEG per uricase tetramer
(Figure 7B). Again, the multiply-PEGylated albumin conjugate
was more potent than free 10 kDa mPEG as an inhibitor of the
binding of anti-PEG antibodies to mPEG-SOD. In this anti-
serum, the IC50 of free mPEG was c. 16 times higher than the
IC50 of mPEG in the mPEG19-albumin conjugate.
Figure 6. Competitive ELISAs were used to compare the inhibition by
mPEG and by PEG diol (HO-PEG-OH) of the binding to mPEG-
SOD of antibodies raised against mPEG2-IFN-α (A), against mPEG-
uricase (B), and against HO-PEG-uricase (C). Concentrations of
competitors are expressed as micromolar PEG in the serum-containing
assay mixtures. (A) Anti-PEG antibodies in serum from a rabbit
immunized with mPEG2-IFN-α bound 10 kDa mPEG (filled circles)
30-fold to 40-fold more tightly than 10 kDa PEG diol (open
circles), regardless of the serum dilution in the range of 1/500 to
1/2000. (B) Anti-PEG antibodies in serum from a rabbit immunized
with mPEG-uricase bound 10 kDa mPEG (●)c . 70 times more
tightly than 10 kDa PEG diol (○). The serum was diluted 1/1000.
(C) Competitive ELISAs of anti-PEG antibodies in serum from a
rabbit immunized with HO-PEG-uricase revealed no preferential
binding of 10 kDa mPEG (●) compared to 10 kDa PEG diol (○),
although the slopes of the competition curves differed. The serum
was diluted 1/500.
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mPEG conjugates, the binding to HO-PEG-SOD of antibodies
raised against HO-PEG-uricase is inhibited to a similar extent
by 10 kDa PEG diol and by a HO-PEG conjugate of albumin
(HO-PEG17-albumin) at all tested competitor concentrations
(Figure 7C).
Figure 7. Competitive ELISAs with mPEG-SOD as the antigen were
used to assess the cooperativity of binding by antibodies raised against
either mPEG2-IFN-α (A) or mPEG-uricase (B) to mPEG in
conjugates with human serum albumin. Competitive ELISAs with
HO-PEG-SOD as the antigen showed similar binding of antibodies
raised against HO-PEG-uricase to free PEG diol and to HO-PEG in an
albumin conjugate (C). Concentrations of all competitors are
expressed as micromolar PEG in the serum-containing assay mixtures.
(A) For anti-PEG antibodies raised against mPEG2-IFN-α, the
concentration of free 10 kDa mPEG (●) that inhibited 50% of the
binding to mPEG-SOD (IC50) was 12 times higher than the IC50 for
mPEG in an mPEG19-albumin conjugate (△). The serum was diluted
1/1000. (B) For anti-PEG antibodies raised against mPEG-uricase, the
IC50 of free 10 kDa mPEG (●) was 16 times higher than the IC50 of
mPEG in an mPEG19-albumin conjugate (△). The serum was
diluted 1/1000. (C) Binding of antibodies raised against HO-PEG-
uricase to HO-PEG-SOD was inhibited to a similar extent by free
10 kDa PEG diol (●)a n db yac o n j u g a t eo fa l b u m i nw i t h1 7
molecules of 10 kDa HO-PEG (□). Because of the low titer of
antibodies detected by direct ELISAs (see Figure 4B), this serum
was diluted only 1/320.
Figure 8. Affinities of antibodies in sera from rabbits immunized with
multiply-PEGylated mPEG conjugates of porcine uricase (A), human
serum albumin (B), or human interferon-α (C) for multiply-
PEGylated conjugates of albumin with mPEG vs HO-PEG were
compared in competitive ELISAsw i t hm P E G - S O Da st h ea n t i g e n .
Concentrations of all competitors are expressed as micromolar
concentrations of PEG in the serum-containing assay mixtures. All of
the sera used for these experiments were diluted 1/1000. (A)
Increasing concentrations of conjugates of albumin containing c. 20
molecules of either 10 kDa mPEG (△) or 10 kDa HO-PEG (□)
were used as competitors for anti-PEG antibodies raised against
mPEG-uricase. The c. 1300-fold ratio of the values of IC50 for the
HO-PEG and mPEG conjugates of albumin is indicated. (B)
Increasing concentrations of conjugates of human serum albumin
with 17 molecules of either 10 kDa mPEG (△) or 10 kDa HO-PEG
(□) were used as competitors for anti-PEG antibodies raised against
mPEG17-albumin. The c. 1600-fold ratio of the values of IC50 for the
HO-PEG and mPEG conjugates of albumin is indicated. (C)
Increasing concentrations of mPEG17-albumin gave a sigmoid
competition curve (△)w i t ha nI C 50 of c. 1 μMm P E Ga n dc o m p l e t e
inhibition at <1 mM mPEG. Since the highest available
concentration of HO-PEG17-albumin (corresponding to c. 1m M
HO-PEG) inhibited only c. 13% of the binding (□), the data for HO-
PEG17-albumin were extrapolated (dashed curve) to provide an
estimate of the relative affinities of the two competitors.
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Proteins Have Much Higher Affinities for Multiply-
PEGylated mPEG-Albumin than for HO-PEG-Albumin
of Similar Composition. As shown in Figure 8A, an mPEG
conjugate of albumin was much more potent than HO-PEG-
albumin as a competitor for the binding to mPEG-SOD of
antibodies raised against mPEG-uricase. The potencies of these
competitors, each of which contained an average of c. 20
molecules of PEG per albumin molecule, differed by a factor of
c. 1300. Indeed, the affinity of the HO-PEG-albumin conjugate
was so low that the binding of the anti-PEG antibodies to the
assay plate was incompletely inhibited by the highest available
concentration of this competitor. Figure 8B illustrates anal-
ogous results obtained in a comparison of the potencies of
mPEG17-albumin vs HO-PEG17-albumin as competitors for the
binding to mPEG-SOD of anti-PEG antibodies raised against
mPEG17-albumin. In this experiment, the highest available con-
centration of HO-PEG17-albumin inhibited only c. 50% of the
binding, and the affinity for mPEG17-albumin was estimated to be
c. 1600 times higher than the affinity for HO-PEG17-albumin.
In analogous experiments performed with antiserum raised
against mPEG2-IFN-α, the affinity of the mPEG-albumin conju-
gate was estimated to be c. 8000 times that of the HO-PEG-
albumin conjugate (Figure 8C). Since the highest available
concentration of the HO-PEG-albumin conjugate inhibited only
c. 13% of the binding, the data were extrapolated to obtain a rough
estimate of IC50 of the HO-PEG-albumin conjugate (see dashed
curve). Thus, anti-PEG antibodies elicited by conjugates of three
proteins containing between 2 and 17 molecules of mPEG per
protein molecule have affinities for multiply-PEGylated conjugates
of albumin with mPEG that are at least 1000-fold higher than their
affinities for HO-PEG albumin with a similar PEG-to-protein ratio.
Antibodies Raised against t-BuO-PEG-Albumin Have
Higher Titers Detected on t-BuO-PEG than on mPEG or
HO-PEG Antigens in Direct ELISAs and Higher Affinities
for t-BuO-PEG than for mPEG or PEG Diol in Compet-
itive ELISAs. Although the focus of this research is the role
of the methoxy group of mPEG in the immune responses to
mPEG-protein conjugates, a few experiments were performed
to quantify and characterize the immune responses to a differ-
ent alkoxy group at the distal terminus of an alkoxyPEG-protein
conjugate. Three rabbits were immunized with a human serum
albumin conjugate of 10 kDa t-BuO-PEG containing an average
of 17 molecules of PEG per molecule of albumin (see Figures 1
and S7). The results of direct ELISAs of serum from one of
these rabbits, in which the assay plates were coated with SOD
conjugates of t-BuO-PEG, mPEG, or HO-PEG, are shown in
Figure 9A. The anti-PEG antibodies generated against t-BuO-
PEG17-albumin show significant cross-reactivity with mPEG-
SOD and slightly less cross-reactivity with HO-PEG-SOD. The
mean titer of antibodies in the sera of these three rabbits
detected with t-BuO-PEG-SOD as the antigen (39000 ± 8000)
was higher than the highest titers of anti-PEG antibodies detected
with mPEG-SOD as the antigen for the groups of rabbits
immunized with mPEG1-IFN-α (see Figure 3A) or mPEG-uricase
(see Figure 4A). As shown in Table 2, the antibodies raised
against t-BuO-PEG17-albumin have slightly higher titers detected
in direct ELISAs with mPEG-SOD than with HO-PEG-SOD as
t h ea n t i g e n ,b u tt h er e l a t i v et i t e r s( d e t e c t e do nm P E G - S O D /
HO-PEG-SOD) for all three rabbits immunized with t-BuO-PEG17-
albumin were lower than those of 10 of 11 rabbits immunized
with mPEG-protein conjugates from which sera from Bleeds 2
and 3 were available.
Figure 9B shows the results of competitive ELISAs of sera from
two rabbits that were immunized with t-BuO-PEG17-albumin, includ-
ing the rabbit for which the results of direct ELISAs are shown in
Figure 9A. About 40-fold higher selectivity of the antibodies raised
against t-BuO-PEG17-albumin for t-BuO-PEG compared to mPEG
is revealed by the results of the competitive ELISAs for both rabbits
(200× in Figure 9B) than by the direct ELISAs (5× in Figure 9A).
MethoxyPEG and HO-PEG Conjugates of Two
Cytokines Have Equivalent Potencies in Cell Culture.
To complement our studies of the immunologic properties
of mPEG and HO-PEG conjugates of various proteins (see
Figures 2−9), experiments were performed to determine
whether the distal terminal group of the polymer affects the
biological activities of PEG conjugates of two cytokines
measured in vitro. Human IFN-α and human EPO were
selected as examples of cytokines for which reliable cell culture
assays of potency were available. MethoxyPEG and HO-PEG
conjugates of IFN-α were tested on human Burkitt’s lymphoma
cells (Daudi cells), the proliferation of which is profoundly
inhibited by IFN-α.
37,38 MethoxyPEG and HO-PEG con-
jugates of EPO were tested on human erythroleukemic cells
Figure 9. Selectivity of antibodies raised against a t-BuO-PEG conjugate
of human serum albumin (t-BuO-PEG17-albumin) was assessed by
direct ELISAs (A) and by competitive ELISAs (B). (A) Direct ELISAs
were performed on assay plates coated with SOD coupled to 10 kDa
HO-PEG (red ◆), to 10 kDa mPEG (black ◆), or to 10 kDa t-BuO-
PEG (green ◆) . In this serum, from rabbit R12059, higher titers
were detected with t-BuO-PEG-SOD than with mPEG-SOD or with
HO-PEG-SOD. (B) Competitive ELISAs were performed on a 1/10
000 dilution of the same serum for which direct ELISA data are shown
in (A) (rabbit R12059; filled symbols, solid curves) and on the same
dilution of serum from a similarly immunized rabbit (R12060; open
symbols, dashed curves). The results revealed a high degree of selectivity of
these antisera for 10 kDa t-BuO-PEG (△, ▲) compared to 10 kDa mPEG
(◇, ◆)o rt o1 0k D aP E Gd i o l( ○, ●).
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and certain other cytokines.
39,40
MonoPEGylated conjugates of IFN-α, synthesized by
reductive alkylation with 20 kDa mPEG aldehyde or 20 kDa
HO-PEG aldehyde (see Figures S1 and S4), were indistinguish-
able in their potencies as inhibitors of Daudi cell proliferation
(Figure 10A). Both conjugates displayed c. 6% of the potency
of unPEGylated IFN-α. Similarly, diPEGylated conjugates of
IFN-α, synthesized using 20 kDa mPEG aldehyde or 20 kDa
HO-PEG aldehyde, were indistinguishable in their potencies as
inhibitors of the proliferation of Daudi cells, although both
were c. 0.4% as potent as unPEGylated IFN-α and c. 7% as
potent as the monoPEGylated conjugates.
The effects on TF-1 cell proliferation of a standard solution
of EPO,
41 a monoPEGylated conjugate of EPO synthesized by
reductive alkylation with 30 kDa HO-PEG aldehyde (see Figure S5),
and a monoPEGylated conjugate of EPO containing 30 kDa
mPEG, which is commercially available from Roche as Mircera,
42,43
were compared (Figure 10B). The potencies of the HO-PEG and
mPEG conjugates of EPO were indistinguishable in this assay,
although both conjugates were only c. 2% as potent as the EPO
standard. Thus, for both IFN-α and EPO, conjugates with HO-
PEG and mPEG had equivalent potencies in cell culture.
■ DISCUSSION
The goal of this research was to assess the role of the methoxy
group of mPEG in the immunogenicity and antigenicity of
mPEG-protein conjugates and the potential advantages of
replacing mPEG with hydroxyPEG (HO-PEG) in the synthesis
of PEG conjugates of proteins and other therapeutic agents.
The results demonstrate that the methoxy groups of mPEG-
protein conjugates contribute significantly to the titers of anti-
PEG antibodies detected in the sera of rabbits immunized with
mPEG conjugates of human interferon-α,h u m a ns e r u m
albumin, or porcine uricase (see Figures 2−4 and Table 2).
Anti-PEG antibodies raised against mPEG conjugates of these
proteins exhibit much higher affinities for multiply-PEGylated
conjugates of albumin synthesized with mPEG than with HO-
PEG (Figure 8). Additional results include the demonstration
that (1) the use of the PEG-containing detergents Tween 20
and Tween 80 decreases the sensitivity of detection of anti-PEG
antibodies by enzyme-linked immunosorbent assays (ELISAs)
(Figure 5); (2) the titers of anti-PEG antibodies formed against
t-BuO-PEG conjugates of albumin were higher than those
elicited by mPEG-albumin conjugates, and (3) analogous HO-
PEG and mPEG conjugates of two cytokines have indistin-
guishable biological activities in cell culture assays (Figure 10).
While the immunologic data were obtained in experiments on
groups of only three rabbits each immunized with an mPEG, a
HO-PEG, or a t-BuO-PEG conjugate of one of three proteins,
the results have intriguing implications for potential improve-
ments in the pharmacokinetics and pharmacodynamics of a
wide range of PEGylated drugs by avoiding the use of activated
mPEG or other alkoxy PEGs in synthesizing the next genera-
tion of such drugs.
Development of Antibodies against PEGylated Ther-
apeutic Enzymes Can Limit Their Efficacy. In 2000, Müller
et al.
44 reported the accelerated clearance of an mPEG conju-
gate of asparaginase (Oncaspar) in a subset of pediatric leukemia
patients who had no clinical evidence of an allergic reaction.
Although there was no mention of anti-PEG antibodies in that
report, subsequent analyses of stored sera from some of the
patients in that study provided clear evidence of anti-PEG anti-
bodies that were detected both by serological techniques and by
flow cytometry.
45 Oncaspar is synthesized by coupling multiple
strands of 5 kDa mPEG to L-asparaginase using the succinimidyl
succinate derivative of mPEG.
9
In 2006, Ganson et al.
30 reported that a subset of patients
with refractory chronic gout who had received a single
subcutaneous injection of an mPEG conjugate of a recombinant
mammalian uricase cleared the conjugate exceptionally rapidly
and that low titers of anti-PEG antibodies (IgG) were detected
in the sera of some of these patients by about one week after
the injection. In a subsequent Phase 1 trial in which the same
mPEG-uricase was administered intravenously to subjects with
refractory chronic gout, antibodies to PEG-uricase, described as
“mostly IgG2 and specific for PEG”, developed in 9 of 24
patients, in some of whom the enzyme was cleared rapidly
without evidence of allergic reactions.
31 The results of a Phase 2
Figure 10. Cell culture assays responsive to human interferon-α
(IFN-α; A) or human erythropoietin (EPO; B) were used to compare
the potencies in vitro of analogous conjugates of these cytokines with
HO-PEG and mPEG. A: Human lymphoma cells (Daudi cells) were
treated for 3 days with serial dilutions of IFN-α (◆), with
monoPEGylated conjugates of IFN-α made with 20 kDa mPEG (▲;
mPEG1-IFN-α) or 20 kDa HO-PEG (△; HO-PEG1-IFN-α), or with
diPEGylated conjugates of IFN-α made with 20 kDa mPEG (■)o r
with 20 kDa HO-PEG (□). After incubation of the cells with Alamar
Blue, the fluorescent signal was measured to quantify cell growth, from
which the percent of inhibitable cell growth was calculated. (B)
Human erythroleukemic cells (TF-1 cells) were treated for 3 days with
serial dilutions of EPO (◆), with a monoPEGylated conjugate with
30 kDa mPEG (▲; mPEG1-EPO; Mircera), or with a monoPEGylated
conjugate with 30 kDa HO-PEG (△;H O - P E G 1-EPO). After
incubation of the cells with Alamar Blue, the fluorescent signal was
measured to quantify cell growth, from which the percent of maximal
cell growth was calculated.
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case) were published in 2008,
46 and the results of two 6-month,
randomized, controlled Phase 3 trials were published in 2011.
47
In the Phase 2 and Phase 3 trials, the absence of high titers of
anti-pegloticase antibodies was correlated with persistent
efficacy of the drug in lowering plasma uric acid concentrations.
In the Phase 3 trials, a subset of the patients lost responsiveness
within 3−4 months of treatment and this loss was associated
with high titers of anti-pegloticase antibodies. However, the
specificities of the antibodies for the enzyme vs the polymer
component of the drug were not reported.
46,47 Pegloticase is
synthesized by coupling an average of ten molecules of 10 kDa
mPEG per subunit of recombinant mammalian uricase
(resembling porcine uricase) using a p-nitrophenylcarbonate
derivative of mPEG.
9,14
These examples of the loss of responsiveness to mPEG conju-
gates of two therapeutic enzymes (asparaginase and uricase) that
were synthesized using two different coupling chemistries sug-
gest the possible clinical relevance of the present studies of the
immunologic responses to mPEG-protein conjugates in experi-
mental animals. The immunogenicity of the polymer compo-
nent of two mPEG-protein conjugates suggests that patients
who have been treated previously with one PEGylated drug may
be at increased risk of adverse immunologic responses to a
second PEGylated drug. Since the asparaginase sequence in
Oncaspar is bacterial
44 and the uricase sequence in pegloticase
is a mutein of porcine uricase,
14 we cannot extrapolate from the
cited results with conjugates of foreign proteins in humans and
rabbits to predict the relative immunogenicities in humans of
mPEG vs HO-PEG conjugates of human proteins.
Anti-PEG Antibodies Formed against HO-PEG-Proteins
Have the Same Titers on mPEG and HO-PEG Antigens
and the Same Mean Affinities for mPEG and PEG Diol. In
contrast with the results obtained for rabbits immunized with
mPEG-proteins, direct ELISAs of sera from each of nine rabbits
immunized with HO-PEG conjugates of IFN-α or uricase had
indistinguishable titers of anti-PEG antibodies detected on
mPEG-SOD and HO-PEG-SOD (see Table 2 and Figures 2B,
3B, and 4B). Similarly, competitive ELISAs show that anti-PEG
antibodies elicited by HO-PEG-uricase do not bind preferen-
tially to 10 kDa mPEG or 10 kDa PEG diol (see Figure 6C).
These results imply that the anti-PEG antibodies elicited by
HO-PEG-proteins are directed against the backbone of the
polymer (see Figure 1) and that competition for their binding
to a PEG-protein antigen is neither enhanced nor inhibited by
the presence of a methoxy group in a competitor.
It should be noted that the titers of anti-PEG antibodies
elicited by HO-PEG conjugates of uricase tended to be lower
than the titers elicited by the corresponding mPEG conjugates
(Figure 4). Therefore, sera from the rabbits immunized with
HO-PEG-uricase were diluted less extensively than sera from
rabbits immunized with mPEG-uricase for competitive ELISAs,
e.g., the sera in Figure 6B and C were diluted 1/1000 and
1/500, respectively. Similarly, the sera in Figure 7B and C were
diluted 1/1000 and 1/320, respectively. Under these condi-
tions, the values of IC50 are not directly proportional to the
affinities of the tested antibodies for the various competitors.
Anti-PEG Antibodies Formed against mPEG-Proteins
Vary in Their Selectivities for the PEG Backbone and the
Methoxy Group. In sera from 10 of 11 rabbits immunized
with mPEG conjugates of three unrelated proteins (human
IFN-α, porcine uricase and human serum albumin), the titers of
anti-PEG antibodies detected by direct ELISAs on assay plates
coated with mPEG conjugates of another unrelated protein,
SOD, were higher than the titers detected in the same sera on
assay plates coated with HO-PEG-SOD (see Table 2 and
Figures 2A, 3A, and 4A]. The unusually high degree of selec-
tivity for mPEG of the anti-PEG antibodies detected in sera
from two of three rabbits immunized with mPEG-uricase
suggests that the immunogenicity of this porcine enzyme to
which the PEG is coupled may influence the impact of the
terminal methoxy groups on the specificity of the antigen-
binding sites of the anti-PEG antibodies (see Figure 1).
There were noteworthy differences within the two groups of
rabbits immunized with mPEG conjugates of porcine uricase
and human serum albumin, respectively. Among those immu-
nized with mPEG-uricase, rabbit R580 had a mean relative titer
of only 3.1 ± 0.6, while rabbits R579 and R581 had mean
relative titers of 20 ± 4.8 and 18 ± 4.8, respectively. Within the
group of rabbits immunized with mPEG17-albumin, the mean
relative titers of rabbits R12056 and R12058 were 3.0 ± 0.5 and
2.6 ± 0.6, respectively. Surprisingly, rabbit R12057 had
indistinguishable titers on mPEG-SOD and HO-PEG-SOD in
triplicate assays (mean relative titer = 1.1 ± 0.1). Rabbit
R12057 was the only 1 of 11 rabbits immunized with mPEG
conjugates of any of three different proteins in which the titer
detected on mPEG-SOD was not at least twice that detected on
HO-PEG-SOD. Competitive ELISAs of sera from that rabbit
also showed no selectivity for mPEG vs PEG diol (data not
shown). The results for this anomalous rabbit do not negate the
overall conclusion about the importance of the methoxy group
in the immune responses of most rabbits to mPEG-protein
conjugates, but they signal the potential role of individual varia-
tion that might impact population studies in humans.
Antibodies against the Terminal Methoxy Group
Dominate the Immune Responses to mPEG-Uricase.
Figure 6B illustrates data from one rabbit immunized with
mPEG-uricase in which the affinity for 10 kDa mPEG was 70
times higher than for 10 kDa PEG diol. Similar results were
obtained when the same serum was tested with 20 kDa mPEG
and 20 kDa PEG diol, as well as when sera from the other two
rabbits immunized with mPEG-uricase were similarly tested
(data not shown). The molecular weight of the methyl group
that differentiates mPEG from HO-PEG is only 15 Da, which
represents only 0.15% of the molecular weight of the 10 kDa
competitors tested in these experiments. Therefore, it may
seem surprising that the anti-PEG antibodies display so much
higher affinities for the small group at the end of the polymer
than for the large number of oxyethylene units (CH2−CH2−O)
within the polymer backbone (c. 227 for 10 kDa PEGs). On the
other hand, the ends of linear or branched polymers, especially
the hydrophobic end containing a methoxy group (as in Figure
6A or B) or a t-butoxy group (as in Figure 9B), are more likely
than the polymer backbone to be accessible to the antigen-
binding sites of the antibodies (see Figure 1). The lack of
absolute specificity of these antibodies for the terminal alkoxy
groups is demonstrated by the observation that a sufficiently
high concentration of PEG diol can completely inhibit the
binding to mPEG-SOD of anti-PEG antibodies raised against
mPEG-IFN-α or mPEG-uricase (see Figure 6A and B).
Multiple PEGylation Amplifies the Detectable Selec-
tivity for mPEG vs HO-PEG of Anti-PEG Antibodies
Formed against mPEG-Proteins. While several FDA-
approved PEGylated therapeutic proteins in clinical use contain
a single strand of mPEG (e.g., PegIntron,
9,48 Neulasta,
9,49 and
Mircera
9,42,43), several others contain derivatives of diPEG-lysine,
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9,48 Macugen,
11
and Cimzia
9,50,51), and others contain multiple strands of
“linear” mPEG (e.g., Adagen,
9,52 Oncaspar,
9,45 Somavert,
9,53
and KRYSTEXXA
9,14,46,47). Our data suggest the potential
clinical relevance of the present studies of the impact of
multiple PEGylation on the antigenicity of mPEG-protein
conjugates.
In contrast with the 12-fold and 16-fold differences between
the affinities of anti-PEG antibodies elicited by two mPEG-
protein conjugates for free 10 kDa mPEG vs an mPEG-albumin
conjugate (see Figure 7A and B), no significant differences were
detected between the affinities or the shapes of the competition
curves obtained with free 10 kDa PEG diol and a HO-PEG-
albumin conjugate as competitors for the binding to HO-PEG-
SOD of antibodies raised against HO-PEG-uricase (see Figure 7C).
A plausible interpretation is that anti-PEG antibodies directed
against the backbone of the polymer can bind cooperatively to
at least two sites within the backbone of a polymer as large as
10 kDa PEG diol. In that case, the presence of multiple strands
of HO-PEG within the albumin conjugate would not further
enhance the cooperativity of the binding. The absence of
enhanced cooperativity in binding multiply-PEGylated protein
conjugates distinguishes anti-PEG antibodies directed against
the polymer backbone from those directed against the methoxy
group(s) at the distal terminus or termini.
Anti-PEG Antibodies Raised against mPEG-Protein Con-
jugates Bind Multiply-PEGylated mPEG-Albumin Conju-
gates >1000-fold More Tightly than HO-PEG-Albumin
Conjugates. In sera from rabbits immunized with mPEG con-
jugates of uricase, albumin or IFN-α, the affinities of anti-PEG
antibodies for mPEG-albumin conjugates were about 3 orders
of magnitude higher than for HO-PEG conjugates of albumin
(Figure 8). Precise estimates of the relative affinities could not
be obtained, since the highest available concentrations of the
HO-PEG-albumin conjugates used as competitors inhibited
only a fraction of the binding of the antibodies to mPEG-SOD
on the assay plate. Su et al.
7 previously reported that anti-PEG
antibodies bind best when PEG is linked to a protein or
liposome or adsorbed on a surface. They also reported that the
binding of their monoclonal antibodies to the PEG backbone
was not influenced by the nature of the terminal groups of the
PEG, which included HO-PEG and mPEG.
The Methoxy Group is Not Unique in Eliciting Anti-
PEG Antibodies Directed against the Terminal Group of
AlkoxyPEG-Protein Conjugates. In sera from three rabbits
immunized with t-BuO-PEG17-albumin (see Figure 9A), the
mean titer detected with t-BuO-PEG-SOD as the antigen was
about 7−10 times higher than the titers detected in sera of
rabbits immunized with mPEG1-IFN-α (see Figure 3A), mPEG-
uricase (see Figure 4A), or mPEG-albumin (data not shown).
The immunogenicity of the t-butoxy group shown in Figure 9
is relevant to the potential use of this group as a removable
blocking group in the synthesis of monofunctionally activated
HO-PEG conjugates.
13 The use of t-BuO-PEG as an inter-
mediate in the synthesis of the p-nitrophenylcarbonate deriva-
tive of HO-PEG (HO-PEG-NPC) is illustrated below:
−−−+ − ⎯ → ⎯− − −
⎯→ ⎯− −
t t BuO PEG OH pNP COCl BuO PEG
NPC HO PEG NPC
[1]
[2]
The failure to remove even a small fraction of the t-butoxy
groups in step [2] of the above reaction sequence would result
in a preparation of HO-PEG-NPC in which traces of t-BuO-
PEG-NPC could form highly immunogenic protein conjugates.
Buffers Containing Tween-Type Non-Ionic Detergents
Interfere with Detection of Anti-PEG Antibodies by ELISAs.
A few previous investigators have recognized the inhibitory
effects of Tween on the detection and quantitation of anti-PEG
antibodies
6,7 and a few companies that sell anti-PEG mAbs warn
their customers to avoid the use of Tween (e.g., Silver Lake
Research
54). The dramatic effects of Tween 20 and Tween 80,
illustrated in Figure 5, have clear implications for clinical studies
that include attempts to quantify anti-PEG antibodies.
6,30,31,45 The
data in Figure 5 and similar results on sera from other rabbits
immunized with mPEG- or HO-PEG-uricase (results not
shown) illustrate the distortion of the results of direct ELISAs
of anti-PEG antibodies resulting from the use of the detergents
Tween 20 and Tween 80, which contain short strands of PEG
within their structures (see Figure 1).
Therapeutic Proteins Coupled to mPEG and HO-PEG
Have Equivalent Potencies in Cell Culture. The in vitro
biological activities of two PEGylated cytokines, one of which
inhibits proliferation (interferon-α) and the other of which
stimulates proliferation (erythropoietin) of the cells on which
each was tested were unaffected by the substitution of HO-PEG
for mPEG of the same molecular weight in their synthesis (see
Figure 10). These results provide support for the proposal that
conjugates synthesized with HO-PEG instead of mPEG will
retain the desirable attributes of PEGylated therapeutic agents,
even if they provoke fewer undesirable immune responses than
those observed with mPEG conjugates.
Implications of These Results for Future Research and
the Future Design and Development of PEGylated Pro-
teins and Other Therapeutic Agents. Our demonstration
that mPEG conjugates of three dissimilar proteins containing as
few as 1 or as many as 17 molecules of mPEG elicit anti-PEG
antibodies that are directed against the methoxy group has
important implications for the clinical use of mPEG conjugates
of enzymes, cytokines, and other therapeutic proteins.
Armstrong et al.
45 recognized that anti-PEG antibodies were
involved in the accelerated clearance of mPEG conjugates of
asparaginase in a subset of patients treated with Oncaspar, and
Ganson, Sundy, and their colleagues recognized that anti-PEG
antibodies were correlated with the accelerated clearance of
pegloticase in a subset of patients.
30,31 However, those reports
did not evaluate the role of the methoxy groups of the mPEGs
in the conjugates being studied.
The results presented above are consistent with the hypoth-
esis that the accelerated clearance and the consequent loss of
efficacy of mPEG conjugates of therapeutic agents might be
decreased by synthesizing next-generation versions of these
drugs with monofunctionally activated derivatives of hydroxy-
PEG, instead of mPEG. The potential advantages of HO-PEG
conjugates have been suggested in previous publications by
several of the present authors.
13,14 Despite the convenience
inherent in the use of mPEG for the synthesis of monofunc-
tionally activated PEGylation reagents, the extra effort entailed
in the use of monofunctionally activated HO-PEG may be jus-
tified by the decreased risk of treatment-limiting immune
responses to the resultant HO-PEG conjugates (see Supporting
Information).
The caveats on extrapolating from the present results to clin-
ical situations include the facts that (1) all immunogens admin-
istered to rabbits in this study were emulsified in complete or
incomplete Freund’s adjuvant, (2) the clearance rates of the
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immune rabbits, and (3) antibody isotyping was not possible in
this study because the secondary antibody used for all of the
reported ELISAs was specific for the H and L chains of rabbit
IgG, which can cross-react with the L chains of rabbit IgM. All
of these factors are worthy subjects of future research. Finally,
although all of the data in this report were obtained with PEG
conjugates of proteins, the potential advantages of replacing
activated mPEG with monofunctionally activated HO-PEG for
synthesizing polymer conjugates of liposomes, viruses, red
blood cells, aptamers, and other types of therapeutic agents also
merit investigation.
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